Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy

Annette Sorensen; Robert J. Mairs; Lynne Braidwood; Craig Joyce; Joe Conner; Sally Pimlott; S. Moira Brown; Marie Boyd

doi:10.1093/mutage/ger068

Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy

Annette Sorensen, Robert J. Mairs, Lynne Braidwood, Craig Joyce, Joe Conner, Sally Pimlott, S. Moira Brown, Marie Boyd

Research output: Contribution to journal › Conference Contribution › peer-review

Abstract

Oncolytic herpes viruses have show promise for the treatment of cancer however it is unlikely that the optimal application of these viruses will be as single therapeutic agents. An alternative strategy would be to utilise these viruses to deliver therapeutic transgenes and enhance their tumour cell killing capacity.

Original language	English
Pages (from-to)	134-135
Number of pages	2
Journal	Mutagenesis
Volume	27
Issue number	1
DOIs	https://doi.org/10.1093/mutage/ger068
Publication status	Published - 2012
Event	34th Annual Meeting of the United Kingdom Environmental Mutagen Society - Nottingham, United Kingdom Duration: 29 Jun 2011 → 1 Jul 2011

Keywords

cancer therapy
oncolysis
gene transfer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/mutage/ger068

3 Article

Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo
Zmuda, F., Malviya, G., Blair, A., Boyd, M., Chalmers, A. J., Sutherland, A. & Pimlott, S. L., 12 Nov 2015, In: Journal of Medicinal Chemistry. 58, 21, p. 8683-8693 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
54 Citations (Scopus)

69 Downloads (Pure)
Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects
Gow, M. D., Seymour, C. B., Mairs, R. J., Boyd, M., Prestiwch, W. V. & Mothersill, C. E., Jan 2014, In: Dose-response : a publication of International Hormesis Society. 12, 1, p. 1-23 23 p.
Research output: Contribution to journal › Article › peer-review
4 Citations (Scopus)
Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution
Barrett, J. A., Joyal, J. L., Hillier, S. M., Maresca, K. P., Femia, F. J., Kronauge, J. F., Boyd, M., Mairs, R. J. & Babich, J. W., Jun 2010, In: Cancer Biotherapy and Radiopharmaceuticals . 25, 3, p. 299-308 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
67 Citations (Scopus)

296 Downloads (Pure)

Cite this

@article{bc0c6311c1444e5f9c4766d30fd2aaa6,

title = "Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy",

abstract = "Oncolytic herpes viruses have show promise for the treatment of cancer however it is unlikely that the optimal application of these viruses will be as single therapeutic agents. An alternative strategy would be to utilise these viruses to deliver therapeutic transgenes and enhance their tumour cell killing capacity.",

keywords = "cancer therapy, oncolysis, gene transfer",

author = "Annette Sorensen and Mairs, {Robert J.} and Lynne Braidwood and Craig Joyce and Joe Conner and Sally Pimlott and Brown, {S. Moira} and Marie Boyd",

year = "2012",

doi = "10.1093/mutage/ger068",

language = "English",

volume = "27",

pages = "134--135",

journal = "Mutagenesis",

issn = "0267-8357",

publisher = "Oxford University Press",

number = "1",

note = "34th Annual Meeting of the United Kingdom Environmental Mutagen Society ; Conference date: 29-06-2011 Through 01-07-2011",

}

TY - JOUR

T1 - Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy

AU - Sorensen, Annette

AU - Mairs, Robert J.

AU - Braidwood, Lynne

AU - Joyce, Craig

AU - Conner, Joe

AU - Pimlott, Sally

AU - Brown, S. Moira

AU - Boyd, Marie

PY - 2012

Y1 - 2012

N2 - Oncolytic herpes viruses have show promise for the treatment of cancer however it is unlikely that the optimal application of these viruses will be as single therapeutic agents. An alternative strategy would be to utilise these viruses to deliver therapeutic transgenes and enhance their tumour cell killing capacity.

AB - Oncolytic herpes viruses have show promise for the treatment of cancer however it is unlikely that the optimal application of these viruses will be as single therapeutic agents. An alternative strategy would be to utilise these viruses to deliver therapeutic transgenes and enhance their tumour cell killing capacity.

KW - cancer therapy

KW - oncolysis

KW - gene transfer

U2 - 10.1093/mutage/ger068

DO - 10.1093/mutage/ger068

M3 - Conference Contribution

SN - 0267-8357

VL - 27

SP - 134

EP - 135

JO - Mutagenesis

JF - Mutagenesis

IS - 1

T2 - 34th Annual Meeting of the United Kingdom Environmental Mutagen Society

Y2 - 29 June 2011 through 1 July 2011

ER -

Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Research output

Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo

Dose calculations for [(131)i] meta-iodobenzylguanidine-induced bystander effects

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

Cite this